Opportunity Information: Apply for PAR 15 130
Apply for PAR 15 130
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Investigations on Primary Immunodeficiency Diseases (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Mar 4, 2015 and posted on Mar 4, 2015.
- Applicants must submit their applications by May 7, 2018. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts County governments City or township governments Small businesses Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Others (see text field entitled Additional Information on Eligibility for clarification) Special district governments Private institutions of higher education For profit organizations other than small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Investigations on Primary Immunodeficiency Diseases (R01)" (Funding Opportunity Number PAR-15-130) is a National Institutes of Health (NIH) discretionary funding announcement that used the R01 research project grant mechanism to support original, investigator-driven biomedical research focused on primary immunodeficiency diseases (PIDDs). The overall aim of the program was to encourage innovative studies that improve how these disorders are found, explained at a molecular level, and ultimately treated. The emphasis is on work that pushes beyond incremental advances and that can open up new directions in understanding and managing inherited or otherwise primary defects of the immune system.
From a scientific standpoint, the FOA highlighted three major areas of interest. First, it encouraged research on detection of primary immunodeficiency diseases, which can include improving diagnostic approaches, developing or validating screening methods, identifying biomarkers, or creating strategies to recognize PIDDs earlier and more accurately in clinical settings. Second, it prioritized identifying the molecular basis of these diseases, meaning studies aimed at uncovering the genetic, cellular, and biochemical mechanisms that cause immune dysfunction. This could involve discovering disease-causing variants, mapping disrupted pathways, clarifying genotype-phenotype relationships, or defining how particular immune cell compartments fail. Third, it sought proposals aimed at the design and preclinical development of innovative therapies, which generally points to therapeutic concepts that can be tested before human trials, such as novel biologics, gene-based approaches, pathway-targeted interventions, or other mechanism-informed strategies assessed in relevant models or preclinical systems.
Administratively, this was a grant (not a contract or cooperative agreement), categorized under health-related research funding, and associated with CFDA program areas 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research). The announcement did not require cost sharing or matching funds, which typically makes participation more feasible for a broad range of institutions because applicants were not expected to contribute a defined percentage of project costs from non-federal sources.
Eligibility was intentionally broad and included many types of domestic organizations and, importantly, also allowed for non-domestic (non-U.S.) entities (foreign organizations), reflecting NIH's interest in supporting strong science wherever it is based, as long as it meets NIH requirements. Eligible applicants listed in the source data included state, county, city, township, and special district governments; federally recognized and other tribal governments and tribal organizations; public and private institutions of higher education; independent school districts; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status; and for-profit organizations (including small businesses and other for-profit entities). The eligibility clarifications also explicitly referenced a range of mission-driven or historically underrepresented institution types and community-based entities, such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, AANAPISIs, and tribally controlled colleges and universities, as well as faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.
In terms of timing, the opportunity was posted and created on March 4, 2015, with an original and final closing date of May 7, 2018, and it was archived on June 7, 2018. That means it is no longer active for new submissions under that specific announcement number, but the scientific scope can still be useful as a guide for understanding what NIH was seeking in this topic area and for finding related or successor opportunities.
For applicants or readers needing the official full text, NIH provided an Additional Information link to the NIH Grants Guide page for PAR-15-130. The contact information in the source data directs technical access or linking problems to the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV, which is a practical detail for anyone who had trouble reaching the electronic announcement rather than a scientific program contact.
Overall, the FOA can be summed up as an NIH R01 funding opportunity designed to accelerate progress in primary immunodeficiency diseases by supporting projects that strengthen diagnosis and detection, define underlying molecular and genetic mechanisms, and advance new treatment concepts through preclinical development, with wide institutional eligibility and no cost-sharing requirement.
Frequently Asked Questions (FAQs): Investigations on Primary Immunodeficiency Diseases (R01) (PAR-15-130)
What is the title and funding opportunity number for this grant?
The opportunity is titled "Investigations on Primary Immunodeficiency Diseases (R01)" and the Funding Opportunity Number (FON) is PAR-15-130.
Which agency offered this funding opportunity?
This was offered by the National Institutes of Health (NIH) as a discretionary funding announcement.
What type of award mechanism does this opportunity use?
The opportunity used the NIH R01 research project grant mechanism.
Is this opportunity a grant, contract, or cooperative agreement?
It was a grant (not a contract and not a cooperative agreement).
What was the overall purpose of PAR-15-130?
The overall aim was to encourage original, investigator-driven biomedical research focused on primary immunodeficiency diseases (PIDDs), with an emphasis on innovative studies that improve detection, explain these disorders at a molecular level, and support progress toward new treatments.
What kinds of projects were emphasized as a good fit?
The announcement emphasized work that goes beyond incremental advances and has the potential to open new directions for understanding and managing inherited or otherwise primary defects of the immune system.
What were the main scientific topic areas of interest?
The FOA highlighted three main areas: (1) detection of PIDDs, (2) identifying the molecular basis of PIDDs, and (3) design and preclinical development of innovative therapies.
What does "detection of primary immunodeficiency diseases" include in this FOA?
Detection-focused research could include improving diagnostic approaches, developing or validating screening methods, identifying biomarkers, or creating strategies to recognize PIDDs earlier and more accurately in clinical settings.
What does "identifying the molecular basis" mean in the context of this FOA?
It refers to studies aimed at uncovering genetic, cellular, and biochemical mechanisms that cause immune dysfunction. Examples mentioned include discovering disease-causing variants, mapping disrupted pathways, clarifying genotype-phenotype relationships, and defining how particular immune cell compartments fail.
What types of therapy development activities were encouraged?
The FOA sought proposals for the design and preclinical development of innovative therapies, including therapeutic concepts that can be tested before human trials, such as novel biologics, gene-based approaches, pathway-targeted interventions, or other mechanism-informed strategies assessed in relevant models or preclinical systems.
Is the research required to be investigator-driven?
Yes. The opportunity is described as supporting original, investigator-driven biomedical research.
What CFDA program areas were associated with this opportunity?
The announcement was associated with CFDA 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research).
Is cost sharing or matching required?
No. The announcement did not require cost sharing or matching funds.
Who was eligible to apply?
Eligibility was broad and included many types of domestic organizations, and it also allowed for non-domestic (non-U.S.) entities (foreign organizations), as long as they meet NIH requirements.
Are non-U.S. (foreign) organizations allowed to apply?
Yes. The opportunity explicitly allowed non-domestic (non-U.S.) entities (foreign organizations).
What types of U.S. government entities were eligible?
Eligible applicants included state, county, city, township, special district governments, and independent school districts.
Are tribal governments and tribal organizations eligible?
Yes. Federally recognized tribal governments, other tribal governments, and tribal organizations were included in the eligible applicant types.
Are colleges and universities eligible?
Yes. Public and private institutions of higher education were eligible.
Are nonprofit organizations eligible?
Yes. Nonprofit organizations with or without 501(c)(3) status were eligible.
Are for-profit organizations eligible?
Yes. For-profit organizations were eligible, including small businesses and other for-profit entities.
Were any specific institution types explicitly referenced as eligible?
Yes. The eligibility clarifications explicitly referenced HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, AANAPISIs, tribally controlled colleges and universities, as well as faith-based or community-based organizations and regional organizations.
Are U.S. territories or possessions included in eligible applicants?
Yes. The eligibility clarifications included U.S. territories or possessions.
Were eligible federal agencies mentioned?
Yes. The eligibility clarifications referenced eligible federal agencies.
When was PAR-15-130 posted and created?
The opportunity was posted and created on March 4, 2015.
What were the closing dates for this opportunity?
The original and final closing date listed was May 7, 2018.
Is this funding opportunity still open for applications?
No. It was archived on June 7, 2018, and is no longer active for new submissions under that specific announcement number.
If it is archived, why might it still be useful to read?
Even though it is no longer active, the scientific scope can still be useful as a guide to what NIH sought in this topic area and for identifying related or successor opportunities.
Where can someone find the official full text of the announcement?
NIH provided an Additional Information link to the NIH Grants Guide page for PAR-15-130.
Who should be contacted for technical access or linking problems to the announcement?
For technical access or linking problems, the source data directs users to contact the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Does the provided contact information appear to be for scientific/program questions?
No. The provided contact is specifically for technical access or linking problems related to reaching the electronic announcement, rather than a scientific program contact.
How can this FOA be summarized in plain terms?
It was an NIH R01 funding opportunity intended to accelerate progress in primary immunodeficiency diseases by supporting projects that strengthen diagnosis and detection, define underlying molecular and genetic mechanisms, and advance new treatment concepts through preclinical development, with wide institutional eligibility and no cost-sharing requirement.
Browse more opportunities from the same category: Health
Next opportunity: Toolkit for Identifying Best Practices on Human Rights Documentation
Previous opportunity: Conservation Innovation Grant (CIG) FY15 Announcement
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 15 130
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 15 130) also looked into and applied for these:
| Funding Opportunity |
|---|
| US Ambassadors HIV and AIDS Community Grant Apply for USEMBASSYSA COMMUNITYGRANTS 2015 Funding Number: USEMBASSYSA COMMUNITYGRANTS 2015 Agency: U.S. Mission to South Africa Category: Health Funding Amount: $30,000 |
| NEI Administrative Supplements to Small Business Innovative Research (SBIR) Grants for the Procurement of Expertise in the Federal Regulatory Approval Process for New Drugs and/or Devices (Admin Supp) Apply for PA 15 132 Funding Number: PA 15 132 Agency: National Institutes of Health Category: Health Funding Amount: $25,000 |
| Biological and Physiological Effects of E cigarette Aerosol Mixtures (R01) Apply for RFA DE 16 004 Funding Number: RFA DE 16 004 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Biological and Physiological Effects of E cigarette Aerosol Mixtures (R21) Apply for RFA DE 16 005 Funding Number: RFA DE 16 005 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| USAID/Zambia Community HIV Prevention Project (Z CHPP) Apply for RFA 611 15 000010 Funding Number: RFA 611 15 000010 Agency: Zambia USAID Lusaka Category: Health Funding Amount: $24,990,000 |
| Validation of Pediatric Patient Reported Outcomes in Chronic Diseases (PEPR) Consortium (U19) Apply for RFA AR 15 014 Funding Number: RFA AR 15 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition National Biocontainment Laboratories (NBLs) Operations Support (UC7) Apply for RFA AI 15 009 Funding Number: RFA AI 15 009 Agency: National Institutes of Health Category: Health Funding Amount: $11,500,000 |
| Maternal and Child Health Epidemiology National and State Coalition Capacity Building to Improve Outcomes Apply for CDC RFA DP15 1507 Funding Number: CDC RFA DP15 1507 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,875,000 |
| Working with Publicly Funded Health Centers to Reduce Teen Pregnancy among Youth from Vulnerable Populations Apply for CDC RFA DP15 1508 Funding Number: CDC RFA DP15 1508 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $650,000 |
| National Public Health Practice and Resource Centers for Children with Attention Deficit/Hyperactivity Disorder or Tourette Syndrome Apply for CDC RFA DD15 1505 Funding Number: CDC RFA DD15 1505 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $900,000 |
| Promoting Access to Guidelines Based Care for People with Asthma Apply for CDC RFA EH15 1503 Funding Number: CDC RFA EH15 1503 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Prescription Drug Overdose Prevention for States Apply for CDC RFA CE15 1501 Funding Number: CDC RFA CE15 1501 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Program Supplement for Addiction Technology Transfer Center (ATTC) Center of Excellence (CoE) on Behavioral Health for Pregnant and Postpartum Women (PPW) and their Families Apply for TI 15 008 Funding Number: TI 15 008 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $365,026 |
| FY15 Announcement of Anticipated Availability of Funds for Support for Expectant and Parenting Teens, Women, Fathers and Their Families Apply for AH SP1 15 001 Funding Number: AH SP1 15 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $800,000 |
| Building Capacity of Professional Planners to Address Public Health Goals Apply for CDC RFA EH15 1505 Funding Number: CDC RFA EH15 1505 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $150,000 |
| Availability of Administrative Supplements to NIGMS Predoctoral Training Grants (Admin Supp) Apply for PA 15 136 Funding Number: PA 15 136 Agency: National Institutes of Health Category: Health Funding Amount: $80,000 |
| Affordable Care Act Program for Early Detection of Certain Medical Conditions Related to Environmental Health Hazards Apply for CDC RFA TS15 1501 Funding Number: CDC RFA TS15 1501 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,500,000 |
| Strengthening Clinical Services for Men Who Have Sex with Men, Transgender, and Bisexual Populations Living with HIV/STI in the Dominican Republic under PEPFAR (Award Category U2G) Apply for CDC RFA GH15 1626 Funding Number: CDC RFA GH15 1626 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| Newborn Screening for Severe Combined Immunodeficiency (SCID) Apply for CDC RFA EH15 1504 Funding Number: CDC RFA EH15 1504 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| Rapid Response to Ebola Viral Disease in West Africa through Strengthening of Surveillance Systems and Disruption of Chain of Transmission Interventions Apply for CDC RFA GH15 1629 Funding Number: CDC RFA GH15 1629 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 15 130", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.